荣晟环保公告，截至2025年10月16日，公司通过上海证券交易所交易系统集中竞价交易方式已累计回购 公司股份835.78万股，占公司截至2025年10月16日总股本2.73亿股的3.07%，回购成交的最高价为13.19 元/股、最低价为10.77元/股，支付的资金总额为人民币9569.31万元（不含交易佣金等交易费用）。本 次回购股份用于减少公司注册资本。 ...

通化东宝(600867.SH)发布公告，公司决定以自有资金回购公司股份用于员工持股计划及/或股权激励。 此次回购股份金额不低于人民币2,000万元(含)，不超过人民币4,000万元(含)，回购股份价格不超过人民 币10元/股(含)。 ...

Group 1 - The company, Tonghua Dongbao (600867.SH), announced a share repurchase plan aimed at employee stock ownership and/or equity incentives [1] - The total amount for the share repurchase will be no less than RMB 20 million and no more than RMB 40 million [1] - The repurchase price will not exceed RMB 10 per share [1]

Core Viewpoint - Tonghua Dongbao (600867) announced a share buyback plan of 20 million to 40 million yuan, aimed at employee stock ownership plans and/or equity incentives, with a maximum buyback price of 10 yuan per share [1] Group 1 - The company plans to repurchase shares worth between 20 million and 40 million yuan [1] - The repurchased shares will be used for employee stock ownership plans and/or equity incentives [1] - The maximum buyback price is set at 10 yuan per share, inclusive [1]

通化东宝公告，拟以2000万元-4000万元回购公司股份，回购价格不超过10元/股。本次回购股份将用于 员工持股计划及/或股权激励。预计回购股份数量不低于200万股且不超过400万股，回购期限为董事会 审议通过本次回购股份方案之日起6个月内。资金来源为公司自有资金。 ...

Core Viewpoint - 康宁杰瑞制药-B (09966) shares increased by over 7%, currently trading at 14.63 HKD with a transaction volume of 37.113 million HKD, following the announcement of a share buyback program [1] Group 1: Share Buyback Announcement - 康宁杰瑞制药 announced a share buyback of 400,000 shares for a total cost of 5.483 million HKD [1] - The company has a maximum buyback limit of 20 million HKD, authorized by the board based on a general mandate approved by shareholders at the annual general meeting on June 12, 2025 [1] Group 2: Upcoming Events - The European Society for Medical Oncology (ESMO) will take place from October 17 to 21 in Berlin, Germany, where the latest research abstracts will be presented [1] - A total of 23 studies from China, including key research on 康宁杰瑞's KN026, have been selected for presentation at the ESMO [1]

2025年 10 月 16 日，公司通过上海证券交易所交易系统以集中竞价交易方式首次回购公司股份275,000 股，占公司当前总股本的比例为 0.03%，回购成交的最高价为10.84元/股，最低价为10.80元/股，成交总 金额为人民币2,975,297.91元（不含印花税、交易佣金等交易费用）。 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 重要内容提示： ■ 一、回购股份的基本情况 公司于 2025年10月10日召开的第四次临时股东大会审议通过了《关于以集中竞价交易方式回购股份预 案的议案》。公司拟通过集中竞价交易方式回购公司已发行的部分人民币普通股（A 股） 股票，回购 股份将全部用于减少注册资本并依法注销。本次回购价格不超过人民币14.97元/股，回购资金总额不低 于人民币10,000万元（含）且不超过人民币20,000万元（含），回购期限自股东大会审议通过本次回购 方案之日起 6 个月内。具体内容详见于2025年10月14日披露的《神马股份关于以集中竞价交易方式回购 股份的回购报告书》（公告编号：2025-100） ...

Core Viewpoint - Shanghai Zhijiang Biological Technology Co., Ltd. plans to repurchase its shares through centralized bidding, with a total amount between RMB 60 million and RMB 120 million, aimed at employee stock ownership plans or equity incentives [2][3][31] Summary by Sections Repurchase Plan Details - The repurchase amount will not be less than RMB 60 million and not exceed RMB 120 million [2][17] - The funding sources for the repurchase will be the company's own funds and special loan funds for stock repurchase, with a loan commitment letter obtained from Beijing Bank [2][19] - The repurchase price will not exceed RMB 37.99 per share, which is 150% of the average trading price over the last 30 trading days prior to the board's decision [3][18] - The repurchase will be conducted through centralized bidding [4][11] - The repurchase period is set for 12 months from the board's approval date [5][12] Purpose and Use of Repurchased Shares - The repurchased shares are intended for employee stock ownership plans or equity incentives, promoting a long-term incentive mechanism [9][31] - If the shares are not transferred within three years after the repurchase, the company will reduce its registered capital accordingly [23][31] Board Meeting and Approval - The board meeting to approve the repurchase plan was held on October 15, 2025, with unanimous approval from all attending directors [7][29] - The repurchase plan does not require shareholder meeting approval as per relevant regulations [8][31] Financial Impact and Structure - As of June 30, 2025, the company's total assets were approximately RMB 3.78 billion, and the net assets attributable to shareholders were about RMB 3.45 billion [20][21] - The repurchase funds will account for approximately 3.18% of total assets and 3.48% of net assets, indicating a manageable impact on the company's financials [20][21] Shareholder and Management Plans - Major shareholders and management have no plans to reduce their holdings in the next three to six months [5][22][31] - The company will comply with legal obligations for information disclosure if any changes occur in shareholding plans [22][31]

Group 1 - The company has approved a share repurchase plan at the fourth extraordinary general meeting held on October 10, 2025, intending to repurchase part of its issued ordinary shares through centralized bidding, with the repurchased shares to be used for capital reduction and cancellation [2][4] - The repurchase price will not exceed RMB 14.97 per share, with a total repurchase fund of no less than RMB 100 million and no more than RMB 200 million, within a period of 6 months from the approval date [2] - As of October 16, 2025, the company has repurchased 275,000 shares, accounting for 0.03% of the total share capital, with a transaction amount of RMB 2,975,297.91, at a maximum price of RMB 10.84 and a minimum price of RMB 10.80 per share [3] Group 2 - The company will strictly adhere to relevant regulations and guidelines during the repurchase period and will make repurchase decisions based on market conditions, ensuring timely disclosure of progress [5]

Core Viewpoint - Jian Sheng Group is actively repurchasing shares, indicating confidence in its future prospects despite its stock price remaining in a low trading range since 2018 [1][3][6] Share Repurchase Details - Jian Sheng Group plans to repurchase shares worth up to RMB 3 billion, with a maximum price of RMB 14.69 per share, potentially acquiring up to 20,422,056 shares, which is approximately 5.96% of its total share capital [4] - The company has previously repurchased a total of 77,956,009 shares since 2018, with a total expenditure of RMB 740 million [8] Management Confidence - In the first half of 2025, company executives collectively increased their holdings, demonstrating their confidence in the company's future [5][6] - Executives and major shareholders have committed to not selling their shares in the short term, reinforcing their belief in the company's stability [5] Financial Performance - Jian Sheng Group's revenue has grown from RMB 1.577 billion in 2018 to RMB 2.574 billion in 2024, with net profit reaching RMB 325 million in 2024 after recovering from a significant loss in 2020 [7][8] - The company has maintained a high dividend payout, distributing over RMB 500 million from 2022 to 2024, with a current dividend yield of 5.27% [8] Stock Price Trends - Despite solid financial performance and dividend distribution, Jian Sheng Group's stock price has fluctuated between RMB 5 and RMB 12 since 2018, significantly lower than its peak of RMB 30.53 in 2017 [3][8] - As of October 16, 2025, the stock closed at RMB 10.49, which is below the maximum repurchase price [4] Debt Situation - The company has a high level of short-term debt, amounting to RMB 977 million, which raises questions about its financial management strategy [8]